ATE316978T1 - Ent-steroide als selektiv wirksame estrogene - Google Patents

Ent-steroide als selektiv wirksame estrogene

Info

Publication number
ATE316978T1
ATE316978T1 AT00925219T AT00925219T ATE316978T1 AT E316978 T1 ATE316978 T1 AT E316978T1 AT 00925219 T AT00925219 T AT 00925219T AT 00925219 T AT00925219 T AT 00925219T AT E316978 T1 ATE316978 T1 AT E316978T1
Authority
AT
Austria
Prior art keywords
steroids
ent
selectively effective
estrogens
effective estrogens
Prior art date
Application number
AT00925219T
Other languages
English (en)
Inventor
Siegfried Schwarz
Dirk Kosemund
Gerd Mueller
Margit Richter
Olaf Peters
Peter Droescher
Walter Elger
Alexander Hillisch
Ulf Boemer
Karl-Heinrich Fritzemeier
Christa Hegele-Hartung
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of ATE316978T1 publication Critical patent/ATE316978T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT00925219T 1999-04-15 2000-04-17 Ent-steroide als selektiv wirksame estrogene ATE316978T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19917930A DE19917930A1 (de) 1999-04-15 1999-04-15 Ent-Steroide als selektiv wirksame Estrogene

Publications (1)

Publication Number Publication Date
ATE316978T1 true ATE316978T1 (de) 2006-02-15

Family

ID=7905255

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00925219T ATE316978T1 (de) 1999-04-15 2000-04-17 Ent-steroide als selektiv wirksame estrogene

Country Status (11)

Country Link
EP (1) EP1169336B1 (de)
JP (1) JP2002542255A (de)
AR (1) AR023497A1 (de)
AT (1) ATE316978T1 (de)
AU (1) AU4401100A (de)
CA (1) CA2371972A1 (de)
CO (1) CO5180552A1 (de)
DE (2) DE19917930A1 (de)
ES (1) ES2258005T3 (de)
PE (1) PE20010042A1 (de)
WO (1) WO2000063228A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350739B1 (en) 1999-08-11 2002-02-26 University Of Florida Resarch Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6958327B1 (en) 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
PT1226155E (pt) * 1999-11-02 2007-07-26 Bayer Schering Pharma Ag 18-nor-esteróides como estrogénios selectivamente activos
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
DE10048634A1 (de) * 2000-09-27 2002-04-18 Jenapharm Gmbh 19-Nor-17alpha-pregna-1,3,5(10)-trien-17beta-ole mit einem 21, 16alpha-Laktonring
CA2427817C (en) 2000-11-03 2009-04-14 Washington University Estrone-derivatives having cytoprotective activity
WO2002040032A2 (en) * 2000-11-17 2002-05-23 Washington University Cytoprotective estrogen derivatives
DE10151365A1 (de) 2001-10-17 2003-04-30 Schering Ag 17-Chlor-D-Homosteroide als selektive Estrogenrezeptorantagonisten
DE60217324T2 (de) 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
DE60234515D1 (de) 2001-05-23 2010-01-07 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
DK1390042T3 (da) 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
DE10151363A1 (de) * 2001-10-17 2003-05-08 Schering Ag Somatotrope Therapie
DE60216630T2 (de) 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
EP1358882A1 (de) * 2002-04-30 2003-11-05 Schering Aktiengesellschaft Verwendung von Prodrogue von Estriol sulfamate zur Behandlung von autoimmunischen Erkrankungen
ES2399423T3 (es) 2002-06-11 2013-04-01 Pantarhei Bioscience B.V. Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método
SI1511496T1 (sl) 2002-06-11 2007-04-30 Pantarhei Bioscience Bv Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo
EP1526856B1 (de) 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
EP1468690B1 (de) * 2003-03-27 2008-10-08 Pantarhei Bioscience B.V. Verwendung von Estrogenen zur Behandlung von Männerunfruchtbarkeit
DE10317922B4 (de) * 2003-04-17 2009-11-26 Presearch Gmbh Verwendung eines Kombinationspräparates aus oralem Kontrazeptivum und Calcium/Vitamin D
DE602008001783D1 (de) 2007-01-08 2010-08-26 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
ES2310968B1 (es) * 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.
JP2011526267A (ja) * 2008-07-03 2011-10-06 バイエル ファーマ アクチエンゲゼルシャフト 化合物および放射性医薬品の製造方法
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
FI3932932T3 (fi) 2013-03-13 2025-10-15 Sage Therapeutics Inc Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス, インコーポレイテッド オキシステロールおよびその使用方法
CN104926916B (zh) * 2015-06-05 2016-08-24 郑祖兰 甾体化合物,含其药物组合物及其制备方法和应用
PT3319611T (pt) 2015-07-06 2021-04-22 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
CA3146266A1 (en) 2019-09-27 2021-04-01 Basf Se Process for the purification of phytosterol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453212A (fr) * 1963-06-05 1966-06-03 Roussel Uclaf Dérivés stéroïdes et procédé de préparation
GB1103871A (en) * 1964-03-11 1968-02-21 Emi Ltd Improvements relating to magnetic matrix stores
FR1509931A (fr) * 1966-04-29 1968-01-19 Roussel Uclaf Procédé de préparation de composés cétoniques optiquement actifs et produits enrésultant
DD235394A3 (de) * 1968-08-30 1986-05-07 Barnikol Oettler Kurt Verfahren zur herstellung von oestradiol-3-methylaether
CA942670A (en) * 1969-07-28 1974-02-26 Richard A. Edgren Contraceptive compositions
ZA81348B (en) * 1980-01-30 1982-02-24 Akzo Nv Novel 17-amino-16-hydroxy steroids of the androstane and oestrane series and derivatives thereof,processes for their preparation and pharmaceutical compositions
US4330540A (en) * 1981-01-29 1982-05-18 Akzo N.V. Ent-16-amino-17-hydroxy-oestra-1,3,5(10)-trienes and derivatives thereof, and pharmaceutical compositions
EP0069424B1 (de) * 1981-07-07 1985-05-29 Akzo N.V. Verfahren zur selektiven Reduzierung von einem 14,17-Dioxo-8,14-Seco-Steroid
FR2717690B1 (fr) * 1994-03-24 1996-04-26 Roussel Uclaf Application de stéroïdes aromatiques 3 substitués par un aminoalcoxy substitué à l'obtention d'un médicament pour contrôler la stérilité, notamment masculine.
FR2718138B1 (fr) * 1994-04-01 1996-04-26 Roussel Uclaf Nouveaux stéroïdes comportant en position 20 une chaîne aminosubstituée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
EP1169336B1 (de) 2006-02-01
EP1169336A1 (de) 2002-01-09
ES2258005T3 (es) 2006-08-16
CO5180552A1 (es) 2002-07-30
PE20010042A1 (es) 2001-02-15
AU4401100A (en) 2000-11-02
JP2002542255A (ja) 2002-12-10
DE60025817D1 (de) 2006-04-13
CA2371972A1 (en) 2000-10-26
DE60025817T2 (de) 2006-11-02
WO2000063228A1 (en) 2000-10-26
DE19917930A1 (de) 2000-10-19
AR023497A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
DE60030764D1 (de) Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
IS6120A (is) Lyfjablanda
DE50012282D1 (de) Sonnendach
DE122007000064I1 (de) Erythropoietinkonjugate
DE10084676T1 (de) Einmallanzettvorrichtung
DE60134094D1 (de) C7-taxanester als antitumormittel
ATA51899A (de) Handstempel
DE60008638D1 (de) Förderbandabstreicher
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
PT1218009E (pt) Grandulos de quetiapina
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
PT1218096E (pt) Microcapsulas de libertacao variavel
ATE313553T1 (de) 16-hydroxyestratriene als selektiv wirksame estrogene
DE60044218D1 (de) em
DE69943245D1 (de) Gaserzeugende zusammensetzung
PT1163256E (pt) Hemi-hidrato de 16-alfa-bromoepiandrosterona
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
PT1235566E (pt) Formulacao injectavel de valnemulina
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE60020682D1 (de) Resorcinenthaltende zusammensetzung
ID27329A (id) Komposisi penghambat
DE10018423B8 (de) Schiebedach
FI991256L (fi) Apulaite tarjoilua varten
ATE440824T1 (de) Nitro-sulfobenzamide
DE60007578D1 (de) Schalteinheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1169336

Country of ref document: EP

REN Ceased due to non-payment of the annual fee